【摘要】 目的为了检测从临床标本中分离的55株奇异变形杆菌对20种抗菌药物的体外活性以及这些杆菌产生超广谱β-内酰胺酶、AmpC酶、金属β-内酰胺酶的情况,正确指导临床合理使用抗生素。方法用API-20E对菌株进行鉴定,双纸片协同试验和确正试验筛选超广谱β-内酰胺酶,纸片扩散法检测AmpC酶,改良Hodge试验检测金属β-内酰胺酶,药敏试验采用标准的纸片扩散法。结果奇异变形杆菌的产酶率为21.8%(12/55)。其中超广谱β-内酰胺酶为18.2%(10/55),AmpC酶为3.6%(2/55)、金属β-内酰胺酶为0%(0/55)。三代头孢菌素、四代头孢菌素、氨曲南、头孢西啶、亚胺培南、阿米卡星和左氧氟沙星的敏感率大于80%。结论实验室有必要加强对产β-内酰胺酶的奇异变形杆菌的检测。三代头孢菌素、四代头孢菌素、氨曲南、头孢西啶、亚胺培南、阿米卡星和左氧氟沙星是治疗奇异变形杆菌感染的首选药物。更多还原

【Abstract】 Objective To determine the activity of 20 antibacterials against 55 steains of proteus mirabilis isolated from clinical specimens so as to guide the rayional application of antibiotics.Methods Identification of the strains was performed by the API20E.Screening extended-spectrum β-lactamases-producing isolates by a double-disk synergy test and a phenotypic confimatory test,AmpC β-lactamases-producing isolates were determined by the disk diffusion method,metallo-β-lactamases-producing isolates were determined by themodified Hodge test.Antibiotic susceptibilities of P.mirabilis isolates were determined by standard disk diffusion.Results The rate of producing β-lactamases of P.mirabilis was 21.8%(12/55),extended-spectrum β-lactamases was 18.2%(10/55),AmpC β-lactamases was 3.6%(2/55),metallo-β-lactamases was 0%(0/55).The sensitive rate of P.mirabilis clinical iaolates to third-generation cephalosporins,fourth-generation cephalosporins,aztreonam,cefoxitin,imipenem,amikacin and levofloxacin were more that 80%.Conclusion Clinical laboratories must strengthen to determine P.mirabilis of lactamases-producing isolates.Third-generation cephalosporins,fourth-generation cephalosporins,aztreonam,cefoxitin,imipenem,amikacin and levofloxacin were the fiest candidate for the infectious conditions cansed by the P.mirabilis.更多还原